Dr. Bart Rijnders is associate professor (UHD) in infectious diseases at the university hospital Erasmus MC in Rotterdam, the Netherlands. He studied medicine and defended his PhD on catheter-related infections at the University of Leuven in Belgium in 2003.
He works as an infectious diseases physician and combines this work with clinical research with a focus on infections in the immunocompromised host. In patients with HIV, clinical studies are performed on the treatment of HIV, side effects of cART, the diagnosis and treatment of sexually transmitted diseases (including HCV in MSM). In patients with an underlying hematological disease research addresses the prevention, diagnosis and treatment of infections in particular invasive fungal infections. As of March 2020, he initiated several multicenter trials on COVID19 in the Netherlands.
Recently completed studies on HIV and HCV addressed issues like the assumed equivalence of FTC and 3TC, TDF renal toxicity, acute HCV therapy with direct activing antivirals (DAHHS1 and DAHHS2 studies), dolutegravir monotherapy as maintenance therapy (DOMONO study), prevalence of IRIS in patients on intergrase inhibitor containing cART (RISING study) and the incidence and outcome of aspergillus coinfection in patients admitted to the ICU for influenza (CIA study).
When not working, Bart enjoys all kinds of endurance sports like cycling, inline skating, or cross-country skiing.
